Fast Track Liver Transplantation: Lessons learned after 10 years running a prospective cohort study with an ERAS-like protocol - 04/04/23

Doi : 10.1016/j.liver.2023.100151 
GP Rodríguez Laiz a, h, , P Melgar Requena a, h, C Alcázar López a, h, M Franco Campello a, C Villodre Tudela a, h, P Bellot García b, h, M Rodríguez Soler b, h, C Miralles Maciá b, h, I Herrera Marante b, h, MT Pomares Mas b, h, P Mas Serrano c, h, L Gómez Salinas d, h, F Jaime Sánchez e, M Perdiguero Gil f, g, h, JM Ramia Ángel a, h, S Pascual Bartolomé b, h
a Hepatobiliary Surgery & Liver Transplantation, Hospital General Universitario Dr. Balmis, Alicante, Spain 
b Hepatology & Liver Unit, Hospital General Universitario Dr. Balmis, Alicante, Spain 
c Pharmacy & Pharmacokinetics, Hospital General Universitario Dr. Balmis, Alicante, Spain 
d Anesthesiology & Surgical Critical Care, Hospital General Universitario Dr. Balmis, Alicante, Spain 
e Critical Care Medicine, Hospital General Universitario Dr. Balmis, Alicante, Spain 
f Nephrology and Renal Transplantation, Hospital General Universitario Dr. Balmis, Alicante, Spain 
g Organ Procurement and Transplant Coordination, Hospital General Universitario Dr. Balmis, Alicante, Spain 
h ISABIAL (Alicante Institute for Health and Biomedical Research), Alicante, Spain 

Corresponding author at: Hospital General Universitario Dr. Balmis, 9ª planta - Secretaría de Cirugía, 03010 Alicante, Spain.Hospital General Universitario Dr. Balmis9ª planta - Secretaría de CirugíaAlicante03010Spain

Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.

Connectez-vous pour en bénéficier!

Abstract

Fast Tracking in Liver Transplantation has been around for the past 25 years, although no substantial advancement, in the form of a comprehensive protocol, had been readily available. Few centers had embraced this goal, so before we started our program, a little over a decade ago, we adopted most of these ideas into a comprehensive pathway that would swiftly carry our patients from the preoperative stage through a safe home discharge. From day one, we have used this Fast Track pathway and applied it prospectively to every single patient undergoing liver transplantation at our institution, monitoring the results periodically. We now report our results after 10 years.

Patients and Methods

All liver transplants performed at our center for the first 10 years since the start of the program (September 2012–September 2022) were included. Our standard protocol included balanced general anesthesia, fluid restriction, avoidance of transfusions, inferior vena cava preservation with temporary porto-caval shunt and thromboelastography. Standard immunosuppression administered included steroids, tacrolimus (delayed in the setting of renal impairment, with basiliximab induction added) and mycophenolate mofetil. Tacrolimus dosing was adjusted using a Bayesian estimation methodology. Oral intake and ambulation were started early.

Results

385 transplants were performed in 367 patients (287♂/80♀) over 120 months, mean age 57.4±9.5 years, raw MELD score 15.4±8.1. Predominant etiologies were alcohol (n=217) and HCV (n=108), with hepatocellular carcinoma present in 197 (53.7%). Eighteen patients underwent combined liver-and-kidney transplants. Mean operating time was 313±66 min with cold ischemia times of 281±85 min. Fifty-nine patients (15.3%) were transfused in the OR (2.3±1.1 units of PRBC). Extubation was immediate (< 30 min) in 365 cases (94.8%). Median ICU length of stay was 12.6 h, and median post-transplant hospital stay was 4 days (2–97) with 55 patients (15.8%) discharged home by the 2nd day, 141 (40.5%) by the 3rd day and 203 (58.3%) by the 4th day, which defined our Fast-Track group. The overall thirty-day-readmission rate was (34.5%), which became significantly lower (27.6% vs 44.1%, p=0.0014) in the Fast-Track group when compared to the regular discharge group. Patient survival was 87.6% at 1 year and 79.7% at 5 years.

Conclusion

Fast-Tracking of Liver Transplant patients is very feasible and can be applied as the standard of care.

Le texte complet de cet article est disponible en PDF.

Keywords : Fast track, Liver transplant, Hospital length of stay, Cost-effectiveness, ERAS, LOS, Early extubation, ICU length of stay

Alphabetical list of abbreviations : ERAS, HBV, HCC, HCV, HRS, ICU, LOS, MELD, NASH, PBC, PTLOS, PRBC, TPCS


Plan


© 2023  The Author(s). Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 10

Article 100151- mai 2023 Retour au numéro
Article précédent Article précédent
  • Cardiovascular assessment of candidates for liver transplant
  • Manuel Lozano, Miguel Molina, Jesús Zarauza, Federico Castillo, Roberto Fernández-Santiago, Edward J. Anderson, Emilio Fábrega, Juan C. Rodríguez-Sanjuán
| Article suivant Article suivant
  • A “return to normalcy” or establishing a “new normal”: The patient experience of liver transplantation
  • Ingrid Woelfel, Daria Faulkner, Sandra Wong, Kenneth Washburn, Austin Schenk

Bienvenue sur EM-consulte, la référence des professionnels de santé.

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.